Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 5
Submit an article Journal homepage
229
Views
66
CrossRef citations to date
0
Altmetric
Original Article: Clinical

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

Alison T. Stopeck Arizona Cancer Center, University of Arizona, Tucson, AZ, USACorrespondence[email protected]
, M.D.,
Joseph M. Unger Southwest Oncology Group Statistical Center, Seattle, WA, USA
,
Lisa M. Rimsza Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
,
William T. Bellamy Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
,
Maria Iannone Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
,
Daniel O. Persky Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
,
Michael Leblanc Southwest Oncology Group Statistical Center, Seattle, WA, USA
,
Richard I. Fisher James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA
&
Thomas P. Miller Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
 show all
Pages 728-735 | Received 19 Jan 2009, Accepted 27 Feb 2009, Published online: 21 Jul 2009

Citations (66)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (11)

Omid Rezahosseini, Sara Hanaei, Mehdi Hamadani, Mahsa Keshavarz-Fathi & Nima Rezaei. (2018) The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. International Reviews of Immunology 37:3, pages 165-173.
Read now
Georgios S. Dimtsas, Eleni C. Georgiadi, Petros Karakitsos, Theodoros P. Vassilakopoulos, Irene Thymara, Penelope Korkolopoulou, Efstratios Patsouris, Christos Kittas & Ipatia A. Doussis-Anagnostopoulou. (2014) Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. Leukemia & Lymphoma 55:3, pages 558-564.
Read now
Danielle Brander, David Rizzieri, Jon Gockerman, Louis Diehl, Thomas Charles Shea, Carlos Decastro, Joseph O. Moore & Anne Beaven. (2013) Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. Leukemia & Lymphoma 54:12, pages 2627-2630.
Read now
Mariam Jamal-Hanjani & Ruth Pettengell. (2011) Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Drug Metabolism & Toxicology 7:11, pages 1441-1448.
Read now
Rena Buckstein, John Kuruvilla, Neil Chua, Christina Lee, David A. Macdonald, Abdulwahab J. Al-tourah, Alison H. Foo, Wendy Walsh, S. Percy ivy, Michael Crump & Elizabeth A. Eisenhauer. (2011) Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. Leukemia & Lymphoma 52:5, pages 833-841.
Read now
Rajni Sinha, Nutan DeJoubner & Christopher Flowers. (2011) Novel agents for diffuse large B-cell lymphoma. Expert Opinion on Investigational Drugs 20:5, pages 669-680.
Read now
Mary J. Ninan, Punit D. Wadhwa & Pankaj Gupta. (2011) Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leukemia & Lymphoma 52:3, pages 360-373.
Read now
Sara Galimberti, Balint Nagy, Eugenio Ciancia, Francesco Caracciolo, Edoardo Benedetti, Matteo Pelosini, Daniele Focosi & Mario Petrini. (2011) Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. Leukemia & Lymphoma 52:1, pages 142-144.
Read now
Deborah Mukherji & Ruth Pettengell. (2010) Pixantrone for the treatment of aggressive non-Hodgkin lymphoma. Expert Opinion on Pharmacotherapy 11:11, pages 1915-1923.
Read now
Javier Briones. (2009) Emerging therapies for B-cell non-Hodgkin lymphoma. Expert Review of Anticancer Therapy 9:9, pages 1305-1316.
Read now
Jia Ruan & John P. Leonard. (2009) Targeting angiogenesis: a novel, rational therapeutic approach for non-Hodgkin lymphoma. Leukemia & Lymphoma 50:5, pages 679-681.
Read now

Articles from other publishers (55)

Alexey V. Emshanov, Denis V. Nesterov, Tatyana N. Sokolova, Priscilla S. Amankwah & Evgeny N. Imyanitov. (2023) Unexpected “Lazarus response” to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer. Exploration of Targeted Anti-tumor Therapy 4:6, pages 1157-1164.
Crossref
Pavani Chalasani, Kiah Farr, Vicky Wu, Isaac Jenkins, Alex Liu, Stephanie Parker, Vijayakrishna K. Gadi, Jennifer Specht & Hannah Linden. (2021) Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer. Breast Cancer Research and Treatment 188:1, pages 91-99.
Crossref
Dominic Kaddu‐Mulindwa, Maciej Rosolowski, Marita Ziepert, Evi Regitz, Gunter Assmann, Moritz Bewarder, Gerhard Held, Michael Pfreundschuh & Jörg Thomas Bittenbring. (2020) VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B‐cell lymphoma. European Journal of Haematology 106:1, pages 100-104.
Crossref
Lei Jiang & Nailin Li. (2020) B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy. Angiogenesis 23:4, pages 515-529.
Crossref
Antonio Giovanni Solimando, Tiziana Annese, Roberto Tamma, Giuseppe Ingravallo, Eugenio Maiorano, Angelo Vacca, Giorgina Specchia & Domenico Ribatti. (2020) New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers 12:7, pages 1869.
Crossref
Lauren Lupino, Tracey Perry, Sandra Margielewska, Robert Hollows, Maha Ibrahim, Matthew Care, Jeremy Allegood, Reuben Tooze, Roger Sabbadini, Gary Reynolds, Roy Bicknell, Zbigniew Rudzki, Ye Lin Hock, Ulises Zanetto, Wenbin Wei, William Simmons, Sarah Spiegel, Ciaran B. J. Woodman, Martin Rowe, Katerina Vrzalikova & Paul G. Murray. (2019) Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma. Leukemia 33:12, pages 2884-2897.
Crossref
Li Wang, Shaoyong Peng, Weipeng Sun & Xiaoxia Liu. (2019) Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B‐cell non‐Hodgkin's lymphoma . European Journal of Haematology 103:3, pages 234-246.
Crossref
Oisun Jung, DeannaLee M. Beauvais, Kristin M. Adams & Alan C. Rapraeger. (2019) VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1. Journal of Cell Science.
Crossref
G. Iacoboni, E. Zucca, M. Ghielmini & A. Stathis. (2018) Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Annals of Oncology 29:5, pages 1120-1129.
Crossref
Ling Li, Sa Xiao, Lei Zhang, Xin Li, Xiaorui Fu, Xinhua Wang, Jingjing Wu, Zhenchang Sun, Xudong Zhang, Yu Chang, Feifei Nan, Jiaqin Yan, Zhaoming Li, Mengyuan Shi, Ken H. Young & Mingzhi Zhang. (2018) An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. Oncotarget 9:22, pages 16213-16219.
Crossref
Rebecca L. King, Grzegorz S. Nowakowski, Thomas E. Witzig, David W. Scott, Richard F. Little, Fangxin Hong, Randy D. Gascoyne, Brad S. Kahl & William R Macon. (2018) Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer Journal 8:3.
Crossref
Rui Zhu, Dan Lu, Yu-Waye Chu, Akiko Chai, Michelle Green, Nancy Zhang & Jin Yan Jin. (2017) Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies. The AAPS Journal 19:3, pages 669-681.
Crossref
Stephen E. Spurgeon, Brian G. Till, Peter Martin, Andre H. Goy, Martin P. Dreyling, Ajay K. Gopal, Michael LeBlanc, John P. Leonard, Jonathan W. Friedberg, Lawrence Baizer, Richard F. Little, Brad S. Kahl & Mitchell R. Smith. (2016) Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. Journal of the National Cancer Institute 109:1, pages djw263.
Crossref
Pavani Chalasani, Marilyn Marron, Denise Roe, Kathryn Clarke, Maria Iannone, Robert B. Livingston, Joseph S. Shan & Alison T. Stopeck. (2015) A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. Cancer Medicine 4:7, pages 1051-1059.
Crossref
Sophie Bernard, Damien Danglade, Laura Gardano, Christelle Laguillier, Gregory Lazarian, Claudine Roger, Catherine Thieblemont, Jacek Marzec, John Gribben, Florence Cymbalista, Nadine Varin-Blank, Dominique Ledoux & Fanny Baran-Marszak. (2015) Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. International Journal of Cancer 136:12, pages 2761-2774.
Crossref
Ranjan Upadhyay, Linda Hammerich, Paul Peng, Brian Brown, Miriam Merad & Joshua Brody. (2015) Lymphoma: Immune Evasion Strategies. Cancers 7:2, pages 736-762.
Crossref
Magdalena Witkowska & Piotr Smolewski. (2015) Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma. Immunotherapy 7:1, pages 37-46.
Crossref
Jing Yang, Wenlu Li, Xin He, Guofei Zhang, Lan Yue & Ying Chai. (2015) VEGF Overexpression Is a Valuable Prognostic Factor for Non-Hodgkin’s Lymphoma Evidence from a Systemic Meta-Analysis. Disease Markers 2015, pages 1-9.
Crossref
Annete Njue, Ann Colosia, Peter C. Trask, Robert Olivares, Shahnaz Khan, Adeline Abbe, Rachel Police, Jianmin Wang, Rodrigo Ruiz-Soto, James A. Kaye & Farrukh Awan. (2015) Clinical Efficacy and Safety in Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review. Clinical Lymphoma Myeloma and Leukemia 15:1, pages 1-12.e7.
Crossref
Zhiying Fu, Jun Zhu, Wen Zheng, Weiping Liu, Zhitao Ying, Yan Xie, Xiaopei Wang, Ningjing Lin, Meifeng Tu, Lingyan Ping, Lijuan Deng, Chen Zhang, Ning Ding & Yuqin Song. (2014) Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma. Cancer Cell International 14:1.
Crossref
Francesca Merchionne, Giovanni Quintana, Francesco Gaudio, Carla Minoia, Giorgina Specchia, Attilio Guarini, Giovanni Quarta, Vincenzo Pavone & Angela Melpignano. (2014) Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. Leukemia Research 38:12, pages 1446-1450.
Crossref
David W. Scott & Randy D. Gascoyne. (2014) The tumour microenvironment in B cell lymphomas. Nature Reviews Cancer 14:8, pages 517-534.
Crossref
Jia Ruan, Stephanie A. Gregory, Paul Christos, Peter Martin, Richard R. Furman, Morton Coleman & John P. Leonard. (2014) Long-Term Follow-Up of R-CHOP With Bevacizumab as Initial Therapy for Mantle Cell Lymphoma: Clinical and Correlative Results. Clinical Lymphoma Myeloma and Leukemia 14:2, pages 107-113.
Crossref
Zachary S. Peacock, Tara Aghaloo, Gary F. Bouloux, Joseph E. CilloJr.Jr., Robert G. Hale, Anh D. Le, Janice S. Lee & Deepak Kademani. (2014) Proceedings From the 2013 American Association of Oral and Maxillofacial Surgeons Research Summit. Journal of Oral and Maxillofacial Surgery 72:2, pages 241-253.
Crossref
David J Stewart & Razelle Kurzrock. (2013) Fool’s gold, lost treasures, and the randomized clinical trial. BMC Cancer 13:1.
Crossref
John P. Chute & Heather A. Himburg. (2013) Imatinib tackles lymphoma via the PDGFRβ+ pericyte. Blood 121:26, pages 5107-5108.
Crossref
Jia Ruan, Min Luo, Chunjie Wang, Lei Fan, Shao Ning Yang, Mariano Cardenas, Huimin Geng, John P. Leonard, Ari Melnick, Leandro Cerchietti & Katherine A. Hajjar. (2013) Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood 121:26, pages 5192-5202.
Crossref
Ewa Lech-Maranda, Jacques Bienvenu, Florence Broussais-Guillaumot, Anne-Sophie Michallet, Krzysztof Warzocha, Przemysław Biliński, Peter Boyle, Bertrand Coiffier & Gilles Salles. (2013) Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma. Archivum Immunologiae et Therapiae Experimentalis 61:2, pages 165-174.
Crossref
Domenico Ribatti, Beatrice Nico, Girolamo Ranieri, Giorgina Specchia & Angelo Vacca. (2013) The Role of Angiogenesis in Human Non-Hodgkin Lymphomas. Neoplasia 15:3, pages 231-238.
Crossref
Fabrice Jardin & Hervé Tilly. 2013. Lymphoma. Lymphoma 177 202 .
Laurie H. Sehn. (2012) Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology 2012:1, pages 402-409.
Crossref
Julian Paesler, Iris Gehrke, Simon Jonas Poll-Wolbeck & Karl-Anton Kreuzer. (2012) Targeting the vascular endothelial growth factor in hematologic malignancies. European Journal of Haematology 89:5, pages 373-384.
Crossref
Sari Riihijärvi, Heidi Nurmi, Harald Holte, Magnus Björkholm, Øystein Fluge, Lars Møller Pedersen, Karin Rydström, Mats Jerkeman, Mikael Eriksson & Sirpa Leppä. (2012) High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. European Journal of Haematology 89:5, pages 395-402.
Crossref
T. Kobayashi, Y. Tsutsumi, N. Sakamoto, H. Nagoshi, M. Yamamoto-Sugitani, Y. Shimura, S. Mizutani, Y. Matsumoto, K. Nishida, S. Horiike, N. Asano, S. Nakamura, J. Kuroda & M. Taniwaki. (2012) Double-hit Lymphomas Constitute a Highly Aggressive Subgroup in Diffuse Large B-cell Lymphomas in the Era of Rituximab. Japanese Journal of Clinical Oncology 42:11, pages 1035-1042.
Crossref
Alison T. Stopeck, Ursa Brown-Glaberman, Hong Yuen Wong, Ben Ho Park, Sara E. Barnato, William J. Gradishar, Clifford A. Hudis & Hope S. Rugo. (2012) The role of targeted therapy and biomarkers in breast cancer treatment. Clinical & Experimental Metastasis 29:7, pages 807-819.
Crossref
Semra Paydas. (2011) Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity. Medical Oncology 29:3, pages 2159-2165.
Crossref
Alison T. StopeckJoseph M. UngerLisa M. RimszaMichael LeBlancBrent FarnsworthMaria IannoneMartha J. Glenn, Richard I. Fisher & Thomas P. Miller. (2012) A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood 120:6, pages 1210-1217.
Crossref
F Mori, T Ishida, A Ito, F Sato, A Masaki, H Takino, M Ri, S Kusumoto, H Komatsu, R Ueda, H Inagaki & S Iida. (2012) Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. Blood Cancer Journal 2:4, pages e67-e67.
Crossref
N. Martis & N. Mounier. (2012) Effets antiangiogéniques dans le traitement des hémopathies malignesThe effect of angiogenesis inhibitors in the treatment of malignant blood disorders. Oncologie 14:4, pages 257-263.
Crossref
Vijay Ramakrishnan, Michael Timm, Jessica L. Haug, Teresa K. Kimlinger, Timothy Halling, Linda E. Wellik, Thomas E. Witzig, S. Vincent Rajkumar, Alex A. Adjei & Shaji Kumar. (2011) Sorafenib, a multikinase inhibitor, is effective in vitro against non‐hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. American Journal of Hematology 87:3, pages 277-283.
Crossref
Yiqing XuNanda MethukuPraveena CoimbatoreTheresa FitzgeraldYiwu HuangYing‐Yi XiaoMurali PagalaShachi Gupta, William SolomonPhilip RubinJohn TreanorAlan AstrowHoward Minkoff & Jay S. Cooper. (2012) Immunogenicity of an Inactivated Monovalent 2009 Influenza A (H1N1) Vaccine in Patients Who Have Cancer. The Oncologist 17:1, pages 125-134.
Crossref
Konstantin Schlick, Ariane Aigelsreiter, Martin Pichler, Sonja Reitter, Peter Neumeister, Gerald Hoefler, Christine Beham-Schmid & Werner Linkesch. (2012) Histiocytic Sarcoma Targeted Therapy: Novel Therapeutic Options? A Series of 4 Cases. Onkologie 35:7-8, pages 447-450.
Crossref
Lale Kostakoglu. (2012) Novel PET Radiotracers for Potential Use in Management of Lymphoma. PET Clinics 7:1, pages 83-117.
Crossref
Jonathan W. Friedberg. (2011) New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice. Clinical Cancer Research 17:19, pages 6112-6117.
Crossref
Tom van Meerten & Anton Hagenbeek. (2011) Novel antibodies against follicular non-Hodgkin’s lymphoma. Best Practice & Research Clinical Haematology 24:2, pages 231-256.
Crossref
T. Melchardt, S. W. Hofbauer, R. Greil & G. Hopfinger. (2011) Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010. memo - Magazine of European Medical Oncology 4:2, pages 120-123.
Crossref
Minna Taskinen, Esa Jantunen, Veli-Matti Kosma, Petri Bono, Marja-Liisa Karjalainen-Lindsberg & Sirpa Leppä. (2010) Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy. European Journal of Cancer 46:13, pages 2506-2512.
Crossref
Sophie Dupire & Bertrand Coiffier. (2010) Targeted treatment and new agents in diffuse large B cell lymphoma. International Journal of Hematology 92:1, pages 12-24.
Crossref
Jia Ruan, Peter Martin, Morton Coleman, Richard R. Furman, Ken Cheung, Adam Faye, Rebecca Elstrom, Mark Lachs, Katherine A. Hajjar & John P. Leonard. (2010) Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 116:11, pages 2655-2664.
Crossref
Semra Paydas. (2010) Anti-angiogenic strategies will be a revolution in lymphoma?. Leukemia Research 34:4, pages 552.
Crossref
Berber D. Roorda, Arja ter Elst, Frank J.G. Scherpen, Tiny G.J. Meeuwsen-de Boer, Willem A. Kamps & Eveline S.J.M. de Bont. (2010) VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27KIP1 via paracrine mechanisms. European Journal of Cancer 46:5, pages 974-982.
Crossref
P. J. Simpson-Haidaris, S. J. Pollock, S. Ramon, N. Guo, C. F. Woeller, S. E. Feldon & R. P. Phipps. (2010) Anticancer Role of PPAR Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes . PPAR Research 2010, pages 1-36.
Crossref
Michael Medinger, Natalie Fischer & Alexandar Tzankov. (2010) Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies. Journal of Oncology 2010, pages 1-13.
Crossref
Dita Gratzinger, Ranjana Advani, Shuchun Zhao, Neha Talreja, Robert J. Tibshirani, Ragini Shyam, Sandra Horning, Laurie H. Sehn, Pedro Farinha, Javier Briones, Izidore S. Lossos, Randy D. Gascoyne & Yasodha Natkunam. (2010) Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). British Journal of Haematology 148:2, pages 235-244.
Crossref
Till SeilerWolfgang HiddemannMartin Dreyling. (2009) Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies. Immunotherapy 1:6, pages 1015-1024.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.